

To
Listing Department,
National Stock Exchange of India Limited.
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

23rd April, 2021

Stock Code: **BALAXI**

Sub: Intimation of setting-up of Step-down Subsidiary

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Balaxi Global DMCC, Dubai ("BGD"), Wholly Owned Subsidiary of the Company has incorporated a Wholly Owned Subsidiary, Balaxi Healthcare Centrafrique, Central African Republic which has consequently become the Step-down subsidiary of Balaxi Pharmaceuticals Limited and the process of subscribing to the shares of Balaxi Healthcare Centrafrique was completed on 22nd April, 2021 as informed by the Subsidiary.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September 2015, are given in Annexure-A.

We request you to kindly take this on record.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**



Chinta Shalini
Company Secretary



Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1342PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

